...
首页> 外文期刊>Journal of Surgical Oncology >Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
【24h】

Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.

机译:淋巴闪烁显像失败后接受第二次放射性同位素注射的乳腺癌患者前哨淋巴结活检的安全性。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND AND OBJECTIVES: A failure to visualize axillary sentinel nodes in lymphoscintigraphy may lead to an unsuccessful sentinel node biopsy (SNB) and subsequent axillary lymph node dissection (ALND). To avoid unnecessary ALND, a second radioisotope injection may be given but has been considered hazardous. We investigated the axillary recurrence rate after tumor-negative SNB in breast cancer patients who received a second tracer injection after axillary visualization failure in lymphoscintigraphy. METHODS: Altogether 1,309 breast cancer patients who underwent a tumor-negative SNB without an ALND were included. Two hundred seven (15.8%) patients received a second tracer injection due to visualization failure in lymphoscintigraphy and 1,102 (84.2%) did not. All patients received a blue dye injection prior to the SNB. The median follow-up time was 43 months. RESULTS: No isolated cancer recurrences were diagnosed in the ipsilateral axilla among patients who received two radioisotope injections. Disease-free survival and overall survival were similar among patients with one or two radioisotope injections (P = 0.122 and P = 0.200, respectively). CONCLUSIONS: Additional radiocolloid tracer injection after axillary non-visualization in lymphoscintigraphy is safe and does not increase axillary recurrence risk after tumor-negative SNB. The results suggest that such patients can be safely managed with SNB without a need to perform an ALND.
机译:背景与目的:在淋巴造影中无法可视化腋下前哨淋巴结可能会导致前哨淋巴结活检(SNB)和随后的腋窝淋巴结清扫术(ALND)失败。为了避免不必要的ALND,可以进行第二次放射性同位素注射,但已被认为是危险的。我们调查了乳腺癌患者中淋巴结显像失败后接受第二次示踪剂注射的乳腺癌患者中,肿瘤阴性SNB后的腋窝复发率。方法:总共纳入了1309名接受了ALND且肿瘤阴性的SNB的乳腺癌患者。 207名(15.8%)患者因淋巴闪烁显像失败而接受了第二次示踪剂注射,而1,102名(84.2%)没有接受。在SNB之前,所有患者均接受了蓝色染料注射。中位随访时间为43个月。结果:在接受两次放射性同位素注射的患者中,同侧腋窝均未诊断出孤立的癌症复发。注射一或两次放射性同位素的患者的无病生存期和总生存期相似(分别为P = 0.122和P = 0.200)。结论:淋巴闪烁显像后腋窝不可视化后再行放射性胶体示踪剂注射是安全的,并且不会增加肿瘤阴性SNB后的腋窝复发风险。结果表明,使用SNB可以安全地治疗此类患者,而无需进行ALND。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号